GMAB
Genmab A/S
Price Chart
Latest Quote
$33.27
Current Price| Previous Close | $32.63 |
| Open | $32.67 |
| Day High | $33.37 |
| Day Low | $32.66 |
| Volume | 878,555 |
Stock Information
| Shares Outstanding | 615.99M |
| Total Debt | $142.00M |
| Cash Equivalents | $3.41B |
| Revenue | $3.85B |
| Net Income | $1.58B |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $20.63B |
| P/E Ratio | 14.59 |
| EPS (TTM) | $2.28 |
| Exchange | NMS |
📊 Custom Metrics & Score
Score: 35/42| Debt to Equity | 0.03 |
| Debt to Earnings | 0.05 |
| Current Ratio | 5.25 |
| Quick Ratio | 5.24 |
| Avg Revenue Growth | 33.59% |
| Profit Margin | 36.44% |
| Return on Equity | 21.38% |
| Avg FCF Growth | 61.58% |
| FCF Yield | 5.05% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $33.27 | 878,555 |
| 2026-01-30 | $32.63 | 1,415,700 |
| 2026-01-29 | $33.35 | 1,189,800 |
| 2026-01-28 | $32.93 | 1,596,900 |
| 2026-01-27 | $34.40 | 2,012,100 |
| 2026-01-26 | $33.47 | 1,343,500 |
| 2026-01-23 | $33.88 | 1,865,700 |
| 2026-01-22 | $33.10 | 1,167,100 |
| 2026-01-21 | $32.95 | 2,282,800 |
| 2026-01-20 | $31.33 | 2,764,500 |
| 2026-01-16 | $32.25 | 6,249,000 |
| 2026-01-15 | $33.85 | 1,966,700 |
| 2026-01-14 | $35.34 | 2,654,200 |
| 2026-01-13 | $33.87 | 2,055,000 |
| 2026-01-12 | $33.95 | 1,476,300 |
| 2026-01-09 | $34.26 | 1,525,200 |
| 2026-01-08 | $33.63 | 970,600 |
| 2026-01-07 | $33.90 | 1,556,600 |
| 2026-01-06 | $33.10 | 1,728,000 |
| 2026-01-05 | $31.80 | 2,165,000 |
About Genmab A/S
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Novartis International AG, Medarex, Inc., ADC Therapeutics SA, Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Immatics, Novo Nordisk A/S, CureVac AG, Anthropic PBC, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
📰 Latest News
Citi Sees a More Supportive Backdrop Forming for AbbVie (ABBV) and Biopharma
Insider Monkey • 2026-01-31T13:31:10Z
EPKINLY Trial Results Prompt Price Target Cut for Genmab (GMAB)
Insider Monkey • 2026-01-30T07:07:17Z
Does AbbVie's Bispecific Trial Win and R&D Pledge Change The Bull Case For AbbVie (ABBV)?
Simply Wall St. • 2026-01-28T01:04:51Z
These Are The 5 Best Stocks To Buy Now Or Watch
Investor's Business Daily • 2026-01-26T17:23:24Z
Genmab (CPSE:GMAB) Valuation Check After Epcoritamab Trial Update And DARZALEX Royalty Momentum
Simply Wall St. • 2026-01-24T23:09:30Z
Alkermes Stock Earns Technical Rating Upgrade
Investor's Business Daily • 2026-01-22T19:16:25Z
Genmab (GMAB)’s Future Potential Underappreciated by Market
Insider Monkey • 2026-01-22T05:21:21Z
Genmab A/S (GMAB) Shares Gain Analyst Support as Deutsche Bank Sees Oncology Upside
Insider Monkey • 2026-01-20T10:00:45Z
Exploring Three High Growth Tech Stocks In Europe
Simply Wall St. • 2026-01-20T05:37:59Z
Does Genmab’s Claude-Powered R&D Push Reshape the Bull Case for Genmab (CPSE:GMAB)?
Simply Wall St. • 2026-01-16T17:08:47Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Reconciled Cost Of Revenue | $137,423,963 | $33,554,655 | $0 | $0 |
| Cost Of Revenue | $137,423,963 | $33,554,655 | $0 | $0 |
| Total Revenue | $3,003,236,788 | $2,445,926,524 | $2,087,681,170 | $1,281,370,124 |
| Operating Revenue | $2,864,278,141 | $2,317,646,779 | $1,969,947,754 | $1,200,532,826 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Interest Expense | $16,742,006 | $10,393,035 | $5,613,207 | $1,979,068 |
| Total Expenses | $2,026,201,239 | $1,655,907,401 | $1,185,682,005 | $831,817,317 |
| Other Income Expense | $179,418,494 | $-88,489,268 | $56,563,854 | $118,896,289 |
| Net Non Operating Interest Income Expense | $122,077,125 | $133,773,206 | $41,019,589 | $28,011,418 |
| Interest Expense Non Operating | $16,742,006 | $10,393,035 | $5,613,207 | $1,979,068 |
| Operating Expense | $1,888,777,276 | $1,622,352,746 | $1,185,682,005 | $831,817,317 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $1,094,369,105 | $646,149,826 | $784,697,535 | $450,161,751 |
| Net Interest Income | $122,077,125 | $133,773,206 | $41,019,589 | $28,011,418 |
| Interest Income | $138,819,131 | $144,166,241 | $46,632,796 | $29,990,485 |
| Normalized Income | $940,794,392 | $714,467,246 | $740,293,484 | $360,428,130 |
| Net Income From Continuing And Discontinued Operation | $1,094,369,105 | $646,149,826 | $784,697,535 | $450,161,751 |
| Total Operating Income As Reported | $935,180,535 | $790,019,123 | $901,999,165 | $449,552,807 |
| Net Income Common Stockholders | $1,094,369,105 | $646,149,826 | $784,697,535 | $450,161,751 |
| Net Income | $1,094,369,105 | $646,149,826 | $784,697,535 | $450,161,751 |
| Net Income Including Noncontrolling Interests | $1,094,369,105 | $646,149,826 | $784,697,535 | $450,161,751 |
| Net Income Continuous Operations | $1,094,369,105 | $646,149,826 | $784,697,535 | $450,161,751 |
| Pretax Income | $1,278,531,168 | $836,936,252 | $999,582,608 | $596,460,514 |
| Special Income Charges | $-41,855,014 | $0 | $0 | - |
| Interest Income Non Operating | $138,819,131 | $144,166,241 | $46,632,796 | $29,990,485 |
| Operating Income | $977,035,549 | $790,019,123 | $901,999,165 | $449,552,807 |
| Gross Profit | $2,865,812,824 | $2,412,371,869 | $2,087,681,170 | $1,281,370,124 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $1.69 | $0.98 | $1.20 | $0.69 |
| Basic EPS | $1.71 | $0.99 | $1.22 | $0.70 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $25,843,781 | $-20,171,848 | $12,159,803 | $29,162,668 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $1,173,475,082 | $979,617,774 | $1,000,734,035 | $517,297,812 |
| Total Unusual Items | $179,418,494 | $-88,489,268 | $56,563,854 | $118,896,289 |
| Total Unusual Items Excluding Goodwill | $179,418,494 | $-88,489,268 | $56,563,854 | $118,896,289 |
| Reconciled Depreciation | $57,620,403 | $43,799,218 | $52,102,074 | $37,754,520 |
| EBITDA (Bullshit earnings) | $1,352,893,577 | $891,128,505 | $1,057,297,889 | $636,194,101 |
| EBIT | $1,295,273,174 | $847,329,287 | $1,005,195,815 | $598,439,581 |
| Diluted Average Shares | $646,329,400 | $659,147,050 | $660,096,040 | $660,457,510 |
| Basic Average Shares | $641,866,470 | $653,097,440 | $657,831,300 | $656,343,000 |
| Diluted NI Availto Com Stockholders | $1,094,369,105 | $646,149,826 | $784,697,535 | $450,161,751 |
| Tax Provision | $184,162,063 | $190,786,426 | $214,885,073 | $146,298,763 |
| Restructuring And Mergern Acquisition | $41,855,014 | $0 | $0 | - |
| Gain On Sale Of Security | $221,273,509 | $-88,489,268 | $56,563,854 | $118,896,289 |
| Research And Development | $1,360,008,929 | $1,132,840,802 | $800,529,656 | $636,498,573 |
| Selling General And Administration | $528,768,346 | $489,511,943 | $385,152,348 | $195,318,744 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $3,044,115,185 | $4,678,201,946 | $3,905,640,553 | $3,340,361,560 |
| Total Assets | $6,391,400,190 | $5,239,425,829 | $4,334,978,914 | $3,749,115,128 |
| Total Non Current Assets | $2,505,301,635 | $319,214,643 | $273,607,853 | $287,878,211 |
| Non Current Deferred Assets | $126,681,176 | $31,476,049 | $36,269,952 | $40,190,295 |
| Non Current Deferred Taxes Assets | $126,681,176 | $31,476,049 | $36,269,952 | $40,190,295 |
| Non Current Accounts Receivable | $7,254,869 | $9,205,259 | $6,908,562 | $4,110,371 |
| Investmentin Financial Assets | $31,809,811 | $19,895,238 | $9,643,202 | $52,369,172 |
| Financial Assets Designatedas Fair Value Through Profitor Loss Total | $31,809,811 | $19,895,238 | - | - |
| Goodwill And Other Intangible Assets | $2,075,729,672 | $14,995,665 | $21,013,544 | $38,667,935 |
| Other Intangible Assets | $1,722,054,802 | $14,995,665 | $146,000,000 | $38,667,935 |
| Current Assets | $3,886,098,555 | $4,920,211,186 | $4,061,371,062 | $3,461,236,917 |
| Inventory | $8,650,036 | $8,462,900 | $0 | - |
| Receivables | $933,506,334 | $734,490,623 | $848,313,879 | $517,297,812 |
| Taxes Receivable | $14,091,188 | $0 | $26,194,965 | $4,719,315 |
| Accounts Receivable | $919,415,146 | $734,490,623 | $822,118,914 | $512,578,497 |
| Cash Cash Equivalents And Short Term Investments | $2,943,942,184 | $4,177,257,664 | $3,213,057,183 | $2,943,939,106 |
| Cash And Cash Equivalents | $1,375,355,768 | $2,207,332,138 | $1,423,883,476 | $1,363,577,545 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Debt | $143,562,699 | $114,323,384 | $85,925,244 | $64,700,285 |
| Long Term Debt And Capital Lease Obligation | $130,727,161 | $100,960,910 | $75,274,543 | $55,261,656 |
| Current Debt And Capital Lease Obligation | $12,835,538 | $13,362,473 | $10,650,700 | $9,438,630 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $1,271,555,332 | $546,228,219 | $408,324,818 | $370,085,633 |
| Total Non Current Liabilities Net Minority Interest | $531,000,614 | $177,423,953 | $145,943,379 | $131,379,638 |
| Tradeand Other Payables Non Current | $4,185,501 | $5,196,517 | $1,583,212 | $1,979,068 |
| Non Current Deferred Liabilities | $396,087,951 | $71,266,525 | $69,085,623 | $74,138,915 |
| Non Current Deferred Taxes Liabilities | $329,119,929 | $0 | - | - |
| Current Liabilities | $740,554,718 | $368,804,266 | $262,381,439 | $238,705,994 |
| Current Deferred Liabilities | $3,348,401 | $4,899,574 | $4,749,637 | $3,958,135 |
| Payables And Accrued Expenses | $724,370,780 | $350,542,219 | $246,981,102 | $225,309,229 |
| Payables | $724,370,780 | $350,542,219 | $246,981,102 | $225,309,229 |
| Other Payable | $485,797,199 | $342,524,735 | $246,981,102 | $225,309,229 |
| Total Tax Payable | $238,573,581 | $8,017,484 | $0 | - |
| Income Tax Payable | $238,573,581 | $8,017,484 | $0 | - |
| Accounts Payable | - | - | - | $350,000,000 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $5,119,844,857 | $4,693,197,610 | $3,926,654,097 | $3,379,029,496 |
| Total Equity Gross Minority Interest | $5,119,844,857 | $4,693,197,610 | $3,926,654,097 | $3,379,029,496 |
| Stockholders Equity | $5,119,844,857 | $4,693,197,610 | $3,926,654,097 | $3,379,029,496 |
| Gains Losses Not Affecting Retained Earnings | $68,363,190 | $8,908,316 | $14,104,981 | $12,331,113 |
| Retained Earnings | $3,285,758,134 | $2,824,381,466 | $2,131,435,398 | $1,525,404,377 |
| Other Equity Adjustments | - | - | $98,000,000 | $12,331,113 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Treasury Shares Number | $2,647,007 | $744,170 | $589,948 | $288,325 |
| Ordinary Shares Number | $63,540,179 | $65,330,365 | $65,371,625 | $65,718,456 |
| Share Issued | $66,187,186 | $66,074,535 | $65,961,573 | $66,006,781 |
| Tangible Book Value | $3,044,115,185 | $4,678,201,946 | $3,905,640,553 | $3,340,361,560 |
| Invested Capital | $5,119,844,857 | $4,693,197,610 | $3,926,654,097 | $3,379,029,496 |
| Working Capital | $3,145,543,836 | $4,551,406,920 | $3,798,989,623 | $3,222,530,923 |
| Capital Lease Obligations | $143,562,699 | $114,323,384 | $85,925,244 | $64,700,285 |
| Total Capitalization | $5,119,844,857 | $4,693,197,610 | $3,926,654,097 | $3,379,029,496 |
| Foreign Currency Translation Adjustments | $68,363,190 | $8,908,316 | $14,104,981 | - |
| Additional Paid In Capital | $1,756,515,431 | $1,850,108,681 | $1,771,614,445 | $1,831,246,432 |
| Capital Stock | $9,208,103 | $9,799,147 | $9,499,273 | $10,047,574 |
| Common Stock | $9,208,103 | $9,799,147 | $9,499,273 | $10,047,574 |
| Non Current Deferred Revenue | $66,968,023 | $71,266,525 | $69,085,623 | $74,138,915 |
| Long Term Capital Lease Obligation | $130,727,161 | $100,960,910 | $75,274,543 | $55,261,656 |
| Current Deferred Revenue | $3,348,401 | $4,899,574 | $4,749,637 | $3,958,135 |
| Current Capital Lease Obligation | $12,835,538 | $13,362,473 | $10,650,700 | $9,438,630 |
| Investments And Advances | $31,809,811 | $19,895,238 | $19,142,475 | $56,479,543 |
| Goodwill | $353,674,870 | $0 | - | - |
| Net PPE | $263,826,106 | $243,642,432 | $190,273,320 | $148,430,067 |
| Accumulated Depreciation | $-116,775,490 | $-100,367,023 | $-71,244,549 | $-56,022,835 |
| Gross PPE | $380,601,596 | $344,009,455 | $261,517,869 | $204,452,902 |
| Leases | $100,591,551 | $101,554,798 | $59,298,493 | $60,894,386 |
| Construction In Progress | $14,370,222 | $5,790,405 | $33,535,313 | $7,916,270 |
| Other Properties | $127,378,760 | $101,851,742 | $75,274,543 | $53,891,532 |
| Machinery Furniture Equipment | $138,261,064 | $134,812,510 | $93,409,519 | $81,750,714 |
| Properties | $0 | $0 | $0 | $0 |
| Inventories Adjustments Allowances | $-2,929,851 | $-2,375,551 | $0 | - |
| Finished Goods | $11,021,820 | $8,759,844 | $0 | - |
| Work In Process | $0 | $0 | $0 | - |
| Raw Materials | $558,067 | $2,078,607 | $0 | - |
| Other Short Term Investments | $1,568,586,417 | $1,969,925,526 | $1,789,173,707 | $1,580,361,560 |
| Other Investments | - | $87,000,000 | $9,499,273 | $4,110,371 |
| Trading Securities | - | $47,000,000 | $9,643,202 | - |
| Buildings And Improvements | - | $686,000,000 | $523,000,000 | $354,000,000 |
| Available For Sale Securities | - | - | $67,000,000 | $52,369,172 |
| Long Term Provisions | - | - | - | $13,000,000 |
| Pensionand Other Post Retirement Benefit Plans Current | - | - | - | $296,000,000 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $1,041,771,304 | $1,039,897,376 | $517,422,531 | $300,818,268 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $1,084,184,385 | $1,095,722,821 | $563,047,827 | $339,181,732 |
| Cash Flow From Continuing Operating Activities | $1,084,184,385 | $1,095,722,821 | $563,047,827 | $339,181,732 |
| Operating Gains Losses | $-221,273,509 | $88,489,268 | $-56,563,854 | $-118,896,289 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-42,413,081 | $-55,825,445 | $-45,625,297 | $-38,363,463 |
| Investing Cash Flow | $-1,382,192,087 | $-190,341,010 | $-397,386,261 | $-146,298,763 |
| Cash Flow From Continuing Investing Activities | $-1,382,192,087 | $-190,341,010 | $-397,386,261 | $-146,298,763 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repurchase Of Capital Stock | $-541,185,334 | $-83,738,167 | $-130,686,970 | $-68,049,477 |
| Financing Cash Flow | $-546,766,003 | $-89,973,988 | $-113,559,493 | $-63,939,106 |
| Cash Flow From Continuing Financing Activities | $-546,766,003 | $-89,973,988 | $-113,559,493 | $-63,939,106 |
| Net Other Financing Charges | $-15,207,322 | $-15,292,608 | $-12,665,698 | $-7,611,798 |
| Net Common Stock Issuance | $-541,185,334 | $-83,738,167 | $-130,686,970 | $-68,049,477 |
| Issuance Of Capital Stock | - | - | - | $0 |
| Common Stock Issuance | - | - | - | $0 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repayment Of Debt | $-8,371,003 | $-13,510,945 | $-10,506,772 | $-8,829,686 |
| End Cash Position | $1,375,355,768 | $2,207,332,138 | $1,423,883,476 | $1,363,577,545 |
| Beginning Cash Position | $2,074,194,989 | $1,468,832,773 | $1,289,166,511 | $1,105,233,111 |
| Effect Of Exchange Rate Changes | $145,934,483 | $-76,908,458 | $82,614,891 | $129,400,571 |
| Changes In Cash | $-844,773,704 | $815,407,823 | $52,102,074 | $128,943,863 |
| Proceeds From Stock Option Exercised | $17,997,656 | $22,567,733 | $40,299,947 | $20,551,855 |
| Common Stock Payments | $-541,185,334 | $-83,738,167 | $-130,686,970 | $-68,049,477 |
| Net Issuance Payments Of Debt | $-8,371,003 | $-13,510,945 | $-10,506,772 | $-8,829,686 |
| Net Long Term Debt Issuance | $-8,371,003 | $-13,510,945 | $-10,506,772 | $-8,829,686 |
| Long Term Debt Payments | $-8,371,003 | $-13,510,945 | $-10,506,772 | $-8,829,686 |
| Net Investment Purchase And Sale | $368,742,675 | $-134,515,566 | $-351,760,964 | $-107,935,300 |
| Sale Of Investment | $1,573,609,018 | $1,484,867,741 | $1,044,056,477 | $2,269,381,541 |
| Purchase Of Investment | $-1,204,866,343 | $-1,619,383,307 | $-1,395,817,441 | $-2,377,316,841 |
| Net Business Purchase And Sale | $-1,708,521,681 | $0 | $0 | - |
| Purchase Of Business | $-1,708,521,681 | $0 | $0 | - |
| Net Intangibles Purchase And Sale | $-16,323,456 | $-1,484,719 | $0 | $0 |
| Purchase Of Intangibles | $-16,323,456 | $-1,484,719 | $0 | $0 |
| Net PPE Purchase And Sale | $-26,089,626 | $-54,340,725 | $-45,625,297 | $-38,363,463 |
| Purchase Of PPE | $-26,089,626 | $-54,340,725 | $-45,625,297 | $-38,363,463 |
| Taxes Refund Paid | $-47,854,233 | $-158,419,546 | $-227,838,627 | $-112,959,087 |
| Interest Received Cfo | $130,448,128 | $134,812,510 | $40,731,732 | $31,665,081 |
| Interest Paid Cfo | $-4,883,085 | $-3,711,798 | $-2,302,854 | $-1,826,832 |
| Change In Working Capital | $-102,963,335 | $202,218,764 | $-264,828,221 | $-107,326,356 |
| Change In Payables And Accrued Expense | $119,565,824 | $92,349,539 | $40,731,732 | $46,279,734 |
| Change In Payable | $119,565,824 | $92,349,539 | $40,731,732 | $46,279,734 |
| Change In Inventory | $-697,584 | $-8,462,900 | $0 | $0 |
| Change In Receivables | $-221,831,575 | $118,332,126 | $-305,559,953 | $-153,606,089 |
| Other Non Cash Items | $-122,077,125 | $-135,406,397 | $-41,019,589 | $-32,882,969 |
| Stock Based Compensation | $100,591,551 | $87,004,549 | $63,184,559 | $47,193,149 |
| Asset Impairment Charge | $16,044,422 | $0 | $0 | - |
| Depreciation Amortization Depletion | $57,620,403 | $43,799,218 | $52,102,074 | $37,754,520 |
| Depreciation And Amortization | $57,620,403 | $43,799,218 | $52,102,074 | $37,754,520 |
| Amortization Cash Flow | $10,882,304 | $3,414,854 | $20,149,973 | - |
| Amortization Of Intangibles | $10,882,304 | $3,414,854 | $20,149,973 | - |
| Depreciation | $46,738,099 | $40,384,364 | $31,952,101 | $37,754,520 |
| Gain Loss On Investment Securities | $-34,460,628 | $-43,502,275 | $94,704,875 | $104,890,580 |
| Net Foreign Currency Exchange Gain Loss | $-186,812,880 | $131,991,543 | $-151,268,729 | $-223,786,870 |
| Net Income From Continuing Operations | $1,278,531,168 | $836,936,252 | $999,582,608 | $596,460,514 |